# Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

> **NCT04720183** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Sulfasalazine
- **DRUG:** GLPG3970

## Key facts

- **NCT ID:** NCT04720183
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2021-04-21
- **Final completion:** 2021-04-23
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720183, "Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04720183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*